SLC5A2 and heart failure: Of the 262 378 patients analysed (n = 131 188 in each group), 10 775 patients from the non‐SGLT2 inhibitor group and 11 567 patients from the SGLT2 inhibitor group were excluded due to a known history of heart failure prior to the period of observation.